跳至主要内容
临床试验/NCT05889156
NCT05889156已完成2 期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 28- Day Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of NST-1024 400 mg BID Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects

NorthSea Therapeutics B.V.31 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年6月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
50
试验地点
31
主要终点
Evaluate the efficacy of NST-1024 by percentage change in TG

研究概览

简要总结

This is a Phase IIa,multicentre proof of concept study consisting of 2 study periods to study Treatment with NST-1024 as an adjunct to diet to reduce triglyceride (TG) levels in subjects with TG levels of ≥500 mg/dL and ≤2000 mg/dL; determined by percentage change in TG from baseline after 28 days of treatment.

The two periods consist of:

  1. A 3-week screening period that includes a TG qualifying period, and
  2. A 28-days, double-blind, randomized, parallel group, placebo-controlled treatment period.

Subjects will return to the study site for a follow-up visit 2 weeks after the last dose.

Approximately 50 subjects will be randomized at approximately 15-30 centres in USA.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 79 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Matched Placebo

Placebo Comparator

干预措施: Placebo (Other)

NST-1024

Active Comparator

NST-1024 400 mg BID

干预措施: NST-1024 (Drug)

结局指标

主要结局

Evaluate the efficacy of NST-1024 by percentage change in TG

时间窗: 4 weeks

Evaluate the efficacy of NST-1024 400 mg BID by assessment of the percentage change in TG from baseline after 28 days of treatment

次要结局

  • Safety Assessments(~ 8 weeks)
  • Change in insulin resistance.(4 weeks)
  • Change in lipoprotein associated phospholipase A2(4 weeks)
  • Percent Change in Lipoprotein a(4 weeks)
  • Percent Change in remnant-like particle cholesterol (RLP-C)(4 weeks)
  • Change in hsCRP(4 weeks)
  • Percent change in Apolipoprotein B and Apolipoprotein C3(4 weeks)
  • Changes in fasting plasma glucose, fasting plasma insulin, and HbA1c(4 weeks)
  • Percent Change in Cholesterol Values(4 weeks)

研究者

发起方
NorthSea Therapeutics B.V.
申办方类型
Industry
责任方
Sponsor

研究点 (31)

Loading locations...

相似试验